Recently, Shinma Drying's engineering team completed a series of small-molecule peptide granulation experiments for a customer using its advanced fluidized bed granulator, further demonstrating the equipment's superior performance in the precision pharmaceutical industry. In these experiments, the fluidized bed granulator equipment successfully processed powdered small-molecule peptide raw materials into uniform granules with a mesh size of 40-60. This not only significantly improved the product's flowability and solubility, but also demonstrated Shinma Drying's deep expertise in the research and development and application of high-end granulation equipment.

Precision Granulation: A Technological Breakthrough in Small-Molecule Peptide Processing

Small-molecule peptides, as important raw materials in the biopharmaceutical industry, suffer from poor flowability, agglomeration, and low dissolution rates in their powdered form, severely limiting subsequent production efficiency and product quality. Shinma Drying's fluidized bed granulator, leveraging innovative fluidized granulation technology, provides a perfect solution to these challenges. During the experiment, the equipment placed small-molecule peptide powder in a fluidized bed. Purified, heated air was used to create a boiling fluidized state, while a binder solution was evenly sprayed in as a fine atomized spray. The airflow thoroughly mixed the powder particles, rapidly combining them with the binder to form primary granules. Continuous hot air drying then rapidly evaporated the moisture from the granules, ultimately resulting in spherical particles with a particle size distribution of 40-60 mesh.

This one-step granulation process not only eliminates the multiple steps of mixing, granulation, and drying required in traditional granulation, but also ensures particle uniformity and porosity through precise airflow control and atomization parameter adjustment. Experimental data showed that the treated small-molecule peptide particles exhibited a 40% improvement in flowability and a 30% increase in dissolution rate in water, fully meeting the stringent requirements for raw material granules used in high-end biopharmaceuticals.

Equipment Advantages: Technological Innovation Drives Enhanced Performance

The Shinma Drying fluidized bed granulator's outstanding performance in small-molecule peptide granulation experiments stems from its multiple core technological advantages. The equipment utilizes an intelligent airflow control system that adjusts the air velocity and pressure within the fluidized bed in real time, ensuring a stable fluidized state for the powder material and preventing localized agglomeration or sedimentation. For sensitive materials such as small molecule peptides, the equipment features a specially designed low-temperature drying mode, ensuring rapid water evaporation while effectively protecting the material's biological activity.

In terms of safety, the equipment is equipped with anti-static filter cloth and explosion-proof pressure relief devices, fully complying with pharmaceutical industry safety regulations. Its zero-dead-angle chamber design eliminates the cleaning difficulties associated with traditional equipment. The mirror-polished interior of the equipment, constructed from 316L stainless steel, ensures that residual material levels are below 0.1%, meeting the highest GMP cleanliness standards. Furthermore, the equipment's modular structure allows for flexible adjustment of granulation parameters based on experimental needs, enabling seamless transition from laboratory trials to pilot production, providing customers with a comprehensive solution from R&D to mass production.

Manufacturer Strength: 20 Years of Experience Establishes Industry Benchmarks

As a leading company in the drying and granulation equipment field, Shinma Drying's 20 years of technological expertise and innovation are a solid foundation for its product performance. The company holds 36 patents related to drying equipment, including patents for the core atomization technology and airflow distribution of its fluidized-bed granulator, which fill a gap in China. Leveraging a 50,000-square-meter modern production base, Shinma Drying achieves full industry-wide control, from core component processing to complete machine assembly. The machining accuracy of key equipment components reaches 0.01mm, ensuring stable and reliable operation of the entire machine.

In the pharmaceutical industry, Shinma Drying has provided over 500 sets of granulation equipment to renowned companies such as Wyeth, Yunnan Baiyao, and Tasly. Its fluidized-bed granulators have maintained a leading market share in the antibiotic, vitamin, and biologics sectors for five consecutive years. The company's technical team consists of 20 senior engineers with an average of over 10 years of experience. They provide comprehensive technical support, from material testing and process optimization to equipment commissioning. This small-molecule peptide granulation experiment exemplifies the team's ability to rapidly respond to customer needs and provide customized solutions to technical challenges.

Industry Impact: Leading the Upgrade of Pharmaceutical Granulation Technology

With the rapid development of the biopharmaceutical industry, the demand for refined processing of raw material granules is becoming increasingly urgent. The successful application of Shinma Drying's fluidized-bed granulator in small-molecule peptide granulation experiments not only provides an advanced technical model for the industry but also promotes the standardization and regularization of pharmaceutical granulation processes. The equipment's integrated "mixing-granulation-drying" process reduces energy consumption by 30% and increases production efficiency by 50% compared to traditional processes. While reducing costs and increasing efficiency, it also significantly reduces human operational errors, providing a strong guarantee for the stability of drug quality.